文献速递头颈与中枢神经肿瘤

胶质母细胞瘤浸润性CD8+ T细胞主要为克隆扩增的GZMK+效应细胞群

Glioblastoma-Infiltrating CD8+ T Cells Are Predominantly a Clonally Expanded GZMK+ Effector Population.
PubMed 文献 · Cancer Discov · 2024-01-01

为理解胶质母细胞瘤(GBM)中T细胞免疫治疗疗效有限的原因,研究对两个队列共15例高级别胶质瘤患者(含GBM及IDH突变型星形细胞瘤4级)的肿瘤浸润淋巴细胞进行转录组与表位测序及单细胞RNA测序联合V(D)J测序。分析显示肿瘤中克隆扩增的GZMK+效应T细胞较配对血液富集,并在蛋白水平验证;整合其他癌种数据发现GBM肿瘤浸润淋巴细胞缺乏典型耗竭CD8+ T细胞群。

要点

  • GBM肿瘤中克隆扩增的GZMK+效应T细胞较配对血液富集,蛋白水平验证一致。
  • 整合其他癌种数据提示GBM肿瘤浸润淋巴细胞缺乏典型耗竭CD8+ T细胞群。
  • 作者认为GZMK+效应T细胞是GBM微环境重要T细胞亚群,可能具有治疗意义。

核心结论

  • GBM肿瘤浸润淋巴细胞以克隆扩增的GZMK+效应T细胞富集为特征,且缺乏典型耗竭CD8+ T细胞群,作者认为这提供了GBM免疫治疗耐药的新潜在机制。

研究设计与样本

  • 对两个队列共15例高级别胶质瘤患者(含GBM或IDH突变型星形细胞瘤4级)的肿瘤浸润淋巴细胞分别进行转录组与表位测序及单细胞RNA测序联合V(D)J测序。

主要发现

  • 与配对血液相比,肿瘤中克隆扩增的GZMK+效应T细胞富集,并在蛋白水平得到验证。
  • 与其他癌种数据整合显示,GBM肿瘤浸润淋巴细胞缺乏典型耗竭CD8+ T细胞群。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Recent clinical trials have highlighted the limited efficacy of T cell-based immunotherapy in patients with glioblastoma (GBM). To better understand the characteristics of tumor-infiltrating lymphocytes (TIL) in GBM, we performed cellular indexing of transcriptomes and epitopes by sequencing and single-cell RNA sequencing with paired V(D)J sequencing, respectively, on TILs from two cohorts of patients totaling 15 patients with high-grade glioma, including GBM or astrocytoma, IDH-mutant, grade 4 (G4A). Analysis of the CD8+ TIL landscape reveals an enrichment of clonally expanded GZMK+ effector T cells in the tumor compared with matched blood, which was validated at the protein level. Furthermore, integration with other cancer types highlights the lack of a canonically exhausted CD8+ T-cell population in GBM TIL. These data suggest that GZMK+ effector T cells represent an important T-cell subset within the GBM microenvironment and may harbor potential therapeutic implications. SIGNIFICANCE: To understand the limited efficacy of immune-checkpoint blockade in GBM, we applied a multiomics approach to understand the TIL landscape. By highlighting the enrichment of GZMK+ effector T cells and the lack of exhausted T cells, we provide a new potential mechanism of resistance to immunotherapy in GBM. This article is featured in Selected Articles from This Issue, p. 897.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Wang AZ, Mashimo BL, Schaettler MO, et al. Glioblastoma-Infiltrating CD8+ T Cells Are Predominantly a Clonally Expanded GZMK+ Effector Population. Cancer Discov. 2024. PMID: 38416133. doi:10.1158/2159-8290.CD-23-0913

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。